JP2017533221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533221A5 JP2017533221A5 JP2017523500A JP2017523500A JP2017533221A5 JP 2017533221 A5 JP2017533221 A5 JP 2017533221A5 JP 2017523500 A JP2017523500 A JP 2017523500A JP 2017523500 A JP2017523500 A JP 2017523500A JP 2017533221 A5 JP2017533221 A5 JP 2017533221A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- administered
- composition according
- trifluoromethylthio
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072299P | 2014-10-29 | 2014-10-29 | |
| US62/072,299 | 2014-10-29 | ||
| US201562199011P | 2015-07-30 | 2015-07-30 | |
| US62/199,011 | 2015-07-30 | ||
| PCT/US2015/057064 WO2016069393A1 (en) | 2014-10-29 | 2015-10-23 | Administration of ubiquitin-activating enzyme inhibitor and radiation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533221A JP2017533221A (ja) | 2017-11-09 |
| JP2017533221A5 true JP2017533221A5 (2) | 2018-11-29 |
| JP6697453B2 JP6697453B2 (ja) | 2020-05-20 |
Family
ID=55858198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523500A Expired - Fee Related JP6697453B2 (ja) | 2014-10-29 | 2015-10-23 | ユビキチン活性化酵素阻害物質及び放射線の投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10335411B2 (2) |
| EP (1) | EP3212651B1 (2) |
| JP (1) | JP6697453B2 (2) |
| TW (1) | TW201628621A (2) |
| WO (1) | WO2016069393A1 (2) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6697453B2 (ja) | 2014-10-29 | 2020-05-20 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ユビキチン活性化酵素阻害物質及び放射線の投与 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2178880B1 (en) | 2007-08-02 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Process for the synthesis of e1 activating enzyme inhibitors |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2814791A4 (en) | 2012-02-17 | 2015-08-19 | Millennium Pharm Inc | PYRAZOLOPYRIMIDINYL INHIBITORS OF ACTIVATION ENZYME OF UBIQUITIN |
| JP6697453B2 (ja) | 2014-10-29 | 2020-05-20 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ユビキチン活性化酵素阻害物質及び放射線の投与 |
-
2015
- 2015-10-23 JP JP2017523500A patent/JP6697453B2/ja not_active Expired - Fee Related
- 2015-10-23 WO PCT/US2015/057064 patent/WO2016069393A1/en not_active Ceased
- 2015-10-23 EP EP15854199.5A patent/EP3212651B1/en active Active
- 2015-10-23 US US15/522,717 patent/US10335411B2/en active Active
- 2015-10-23 TW TW104135034A patent/TW201628621A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533221A5 (2) | ||
| JP2016536286A5 (2) | ||
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| JP2017533223A5 (2) | ||
| EA202092671A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
| JP2016515561A5 (2) | ||
| JP2018502120A5 (2) | ||
| JP2015529225A5 (2) | ||
| JP2006504723A5 (2) | ||
| JP2015527318A5 (2) | ||
| JP2013501731A5 (2) | ||
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX373301B (es) | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. | |
| JP2016532667A5 (2) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP7270235B2 (ja) | ペンタアザ大環状環複合体による組み合わせ癌免疫療法 | |
| JP2014525454A5 (2) | ||
| JP2014534269A5 (2) | ||
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2019524820A5 (2) | ||
| JP2016515550A5 (2) |